Long Name Amyloid imaging to prevent Alzheimer’s disease
Description Amyloid imaging to prevent Alzheimer’s disease. Deposits of beta amyloid protein in the brain are a common sign of Alzheimer’s disease. AMYPAD will study the value of using positron emission tomography (PET) imaging to scan people’s brains for beta amyloid deposits. AMYPAD will carry out beta amyloid PET imaging on an unprecedented number of people who are suspected to be in the early stages of Alzheimer’s disease. The goal is to determine the clinical added value of PET imaging in diagnosis and patient monitoring, and to develop data to establish its usefulness in clinical trials. AMYPAD will work closely with IMI’s EPAD project, which is working to increase our understanding of the early stages of dementia and creating a platform to test treatments designed to prevent dementia.
Objectives 1. Improve the diagnostic workup of patients suspected to have AD (3) and their management. 2. Understand the natural history of AD in a pre‐symptomatic stage in order to better select patients for trials. 3. Monitor change in β‐amyloid deposition to quantify the impact of novel therapies.
Start date 01-10-2016
End date 30-09-2022
Name Projects Type of institution Country  
Synapse Research Management Partners SL EPAD AMYPAD NEURONET EMIF ROADMAP SME Spain
University Of Edinburgh EPAD AMYPAD EQIPD ROADMAP Academia United Kingdom
Alzheimer Europe EPAD AMYPAD MOPEAD AETIONOMY EMIF RADAR-AD ROADMAP NEURONET Pharma-Cog EPND Patient/carers organisation Luxembourg
Centre Hospitalier Universitaire De Toulouse EPAD AMYPAD Academia France
Fundacio Barcelonabeta Brain Research Center EPAD AMYPAD AETIONOMY Academia Spain
Karolinska Institutet EPAD AMYPAD MOPEAD AETIONOMY EMIF RADAR-AD Academia Sweden
Klinikum Der Universitaet Zu Koeln EPAD AMYPAD MOPEAD ADAPTED Academia Germany
Stichting Katholieke Universiteit / Radboud University Nijmegen Medical Centre EPAD EQIPD PRISM AMYPAD PD-MitoQUANT PRISM2 Academia Netherlands
VU University Medical Center Amsterdam EPAD AMYPAD IM2PACT PRISM MOPEAD RADAR-CNS RADAR-AD EMIF PRISM2 Pharma-Cog EPND Academia Netherlands
Universite De Geneve EPAD AMYPAD EPND Academia Switzerland
University College London AMYPAD PD-MitoQUANT PHAGO EMIF Academia United Kingdom
Life Molecular Imaging LTD AMYPAD Other United Kingdom
GE healthcare Ltd AMYPAD ROADMAP EFPIA United Kingdom
WP number Description Project  
WP1 Overall project governance and management AMYPAD
WP2 Tracer delivery, PET scanning and Image analysis AMYPAD
WP3 Diagnostic and Patient Management Study AMYPAD
WP4 Risk stratification: Natural history and enrichment strategies AMYPAD
WP5 Monitoring treatment: Quantifying patient-specific efficacy AMYPAD
WP6 Ethics, communication and dissemination AMYPAD
Deliverable number Title Project Submission date Link Keywords  
D1.2 Project Handbook, including the internal communication tools AMYPAD 09-04-2019
D2.1 Tracer strategy & Site Selection AMYPAD 01-01-2017
D1.1 Report on AMYPAD governance and relationship with EPAD AMYPAD 01-02-2017
D6.1 Initial communication Plan, including project branding and policies AMYPAD 01-03-2017
D3.1 Report on feedback from EMA on design of diagnostic study AMYPAD 01-04-2017
D2.4 Image database and SUVR quantification methods implemented AMYPAD 01-04-2017
D2.3 Operating Process Document (methodology and processes) AMYPAD 01-04-2017
D2.2 Clinical Imaging network set up & sites certified AMYPAD 11-11-2020
D1.3 Initial Data & Knowledge Management Plan AMYPAD 01-04-2017
D6.3 Initial report on Dissemination tools AMYPAD 11-11-2020
D4.1 Set-up of the EPAD/AMYPAD Collaboration Framework AMYPAD 01-09-2017
D6.2 Ethics Policy and Guidance Document AMYPAD 01-10-2017
D3.2 First study subject approval package AMYPAD 01-10-2017
D6.4 Report on public access policies AMYPAD 01-10-2017
D5.1 Collection of existing data and development of analysis strategy AMYPAD 11-11-2020
D4.2 EPAD/AMYPAD Protocol with regulatory approval AMYPAD 01-10-2017
D3.3 Amyloid PET quantification protocol and imaging charter AMYPAD 01-04-2018
D2.5 Online platform for data sharing AMYPAD 01-04-2018
D4.3 Site selection from EPAD network complete AMYPAD 01-07-2018
D6.6 Report from the Ethics Advisory - AMYPAD Year 1 AMYPAD 01-07-2018
D6.7 Report from the Ethics Advisory - AMYPAD Year 2 AMYPAD 01-11-2018
D5.3 Interim report on basic disease modelling AMYPAD 01-02-2019
D6.5 Initial Report on dissemination activities and communication strategy update AMYPAD 11-11-2020
D4.7 Mid-term Recruitment Report (Month 30) Quarterly report V1.0 AMYPAD 11-11-2020
D3.6 Mid-term Recruitment Report (Month 30) AMYPAD 01-04-2019
D1.4 Interim report on project progress AMYPAD 01-04-2019
D4.4 Mid-term Recruitment Report AMYPAD 01-07-2019
D5.2 Report on the preliminary Scientific Advice from regulatory bodies AMYPAD 01-07-2019
D3.4 Mid-term Recruitment Report AMYPAD 01-07-2019
D4.8 Report on selection criteria for repeat imaging AMYPAD 01-10-2019
D4.6 All approval packages AMYPAD 01-10-2019
D4.5 Mid-term Recruitment Report AMYPAD 01-10-2019
D3.8 All approvals package AMYPAD 01-10-2019
D3.7 Disclosure of amyloid PET results to persons with subjective cognitive decline - an AMYPAD sub-study AMYPAD 01-10-2019
D3.5 Mid-term Recruitment Report AMYPAD 01-10-2019
D1.5 Interim Data & Knowledge Management Plan AMYPAD 01-10-2019
D6.8 Report from the Ethics Advisory - AMYPAD Year 3 AMYPAD 01-11-2019
D3.9 Mid-term recruitment report AMYPAD 01-01-2020
D2.6 Descriptive Report on amyloid PET scan quantification I AMYPAD 01-01-2020
D4.9 Mid-term recruitment report AMYPAD 01-01-2020
D3.11 Mid-term recruitment report Quarterly report V5 AMYPAD 01-03-2020
D5.4 Interim report on advanced disease modelling AMYPAD 01-04-2020
D3.10 Baseline clinical and amyloid-PET features (M42) AMYPAD 01-04-2020
D4.11 Mid-term Recruitment Report V6 AMYPAD 01-07-2020
D3.12 Mid-term recruitment report Quarterly report V6 AMYPAD 01-07-2020
D3.13 Mid-term Recruitment Report AMYPAD 01-10-2020
D4.12 Mid-term Recruitment Report AMYPAD 01-10-2020
D4.13 Disease modelling report v1 AMYPAD 01-10-2020
D4.14 Integration of non-EPAD cohorts AMYPAD 01-10-2020
D1.6 Project assessment AMYPAD 01-11-2020
D2.7 Descriptive Report of Amyloid PET Scan Quantification II AMYPAD 30-11-2020 amyloid, quantification, data, cerebellum, csf, biomarkers, patient, analysis, imaging,
D6.9 Report from the Ethics Advisory - AMYPAD Year 4 AMYPAD 01-11-2020
D4.15 Mid-term Recruitment Report V8 AMYPAD 01-02-2021
D3.15 Mid-term recruitment report Quarterly report V8 AMYPAD 07-07-2022
D4.16 Mid-term Recruitment Report V9 AMYPAD 01-04-2021
D3.16 Mid-term recruitment report Quarterly report V9 AMYPAD 01-04-2021
D4.17 Mid-term recruitment report V10 AMYPAD 01-08-2021
D3.17 Mid-term recruitment report Quarterly report V10 AMYPAD 29-08-2021
D6.10 Report on the perspective of research participants on disclosing amyloid PET imaging biomarkers AMYPAD 29-10-2021
D6.12 Final report on ethics AMYPAD 29-10-2021
D4.21 Mid-term Recruitment Report V11 AMYPAD 29-10-2021
D6.13 Report from the Ethics Advisory - AMYPAD Year 5 AMYPAD 29-11-2021
D3.18 Final Report on Recruitment (DPMS) AMYPAD 29-11-2021
D2.8 Descriptive Report of Amyloid PET Scan Quantification III AMYPAD 29-12-2021
D4.22 Mid-term Recruitment Report V12 AMYPAD 29-01-2022
D3.19 Impact of amyloid PET on diagnosis, treatment, and adverse health outcomes AMYPAD 06-07-2022
D4.23 Mid-term Recruitment Report V13 AMYPAD 29-04-2022
Title First author last name Year Project Link Keywords  
Faster PET reconstruction with a stochastic primal-dual hybrid gradient method Ehrhardt 2017 AMYPAD Conference proceedings, brain imaging, Positron emission tomography, Inverse problems, Optimization (mathematics), Reconstruction algorithms, Convex optimization
NiftyPET: a High-throughput Software Platform for High Quantitative Accuracy and Precision PET Imaging and Analysis Markiewicz 2018 AMYPAD Informatics research paper, PET, quantification, Image reconstruction, uncertainty, bootstrap, scatter correction, random events estimation, partial volume correction, normalisation
The Rationale Behind the New Alzheimer’s Disease Conceptualization: Lessons Learned During the Last Decades Molinuevo 2018 AMYPAD Review article, Alzheimer’s disease, biomarkers, continuum, ethical challenges, preclinical, prevention
Assessing Amyloid Pathology in Cognitively Normal Subjects using [18F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods Collij 2018 AMYPAD Clinical research paper, 18F-flutemetamol PET, amyloid pathology, visual assessment, preclinical Alzheimer disease
AMYPAD Diagnostic and Patient Management Study: Rationale and design Frisoni 2018 AMYPAD Clinical study protocol, PET, amyloid, brain imaging, cognitive decline, Alzheimer's disease
Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies Heeman 2019 AMYPAD Clinical research paper, amyloid, quantification, simplified methods, flutemetamol PET, florbetaben PET, Alzheimer’s disease
IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease Frisoni 2019 AMYPAD Opinion paper, PET, amyloid, Alzheimer's disease, tau
Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease Archetti 2019 AMYPAD Clinical research paper, Alzheimer's disease, event-based models, inter-cohort validation, biomarkers progression, patient staging
Simulating the effect of cerebral blood flow changes on regional quantification of [18F]flutemetamol and [18F]florbetaben studies Heeman 2020 AMYPAD Clinical research paper, Alzheimer’s disease, amyloid PET, cerebral blood flow, quantification, simulation study
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study Lopes Alves 2020 AMYPAD Clinical research paper, alzheimer's disease, PET, amyloid, clinical trial
The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging Fantoni 2019 AMYPAD amyloid PET, staging, spatial-temporal ordering, pathology
Multitracer model for staging cortical amyloid deposition using PET imaging Collij 2020 AMYPAD PET imaging, Amyloid, Alzheimer’s disease, Staging, Cognition
[11C]PIB amyloid quantification: effect of reference region selection Heeman 2020 AMYPAD [11C]PiB, Alzheimer’s disease, Amyloid PET, Quantification, Reference regions
The Framing of “Alzheimer’s Disease”: Differences Between Scientific and Lay Literature and Their Ethical Implications Smedinga 2020 AMYPAD Biomarkers, Dementia, Ethics, Framing analysis, Metaphor
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias Chetelat 2020 AMYPAD biomarkers, amyloid, diagnostic
The effects of age on resting-state BOLD signal variability is explained by cardiovascular and cerebrovascular factors Tsvetanov 2020 AMYPAD aging, cerebral vascular reactivity, functional magnetic resonance imaging (fMRI), individual differences.
Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients Boccardi 2020 AMYPAD Alzheimer’s disease, MCI, biomarker, biomarker-based diagnosis, consensus recommendations, diagnosis, diagnostic algorithm. implementation. multiple biomarkers
The characterisation of subjective cognitive decline Jessen 2020 AMYPAD Review article, clinical research, subjective cognitive decline, Alzheimer's disease, neurodegeneration
Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity Sala 2020 AMYPAD csf, biomarkers, pet, baseline, alzheimer, accumulation, pathology, biomarker, disease, brain
Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease‐modifying therapies Frisoni 2020 AMYPAD
Uncertainty analysis of MR-PET image registration for precision neuro-PET imaging Markiewicz 2021 AMYPAD PET, MR, Registration, Precision, Partial volume correction, Amyloid, Alzheimer’s disease
Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent Collij 2021 AMYPAD Amyloid PET, [18F]flutemetamol, Regional visual read, Centiloid, Sensitivity, Neuropathology
Early detection of amyloid load using 18 F-florbetaben PET Bullich 2021 AMYPAD Alzheimer’s disease; Amyloid-beta; Florbetaben; Mild cognitive impairment; PET; Subjective memory complainers.
Parametric imaging of dual-time window [18F] flutemetamol and [18F] florbetaben studies Heeman 2021 AMYPAD Amyloid PET, [18F]flutemetamol, [18F]florbetaben, Parametric imaging, PET quantification
Diagnostic value of amyloid-PET and tau-PET a head-to-head comparison Altomare 2021 AMYPAD Alzheimer Disease* / diagnostic imaging Amyloid Amyloid beta-Peptides, Amyloidosis, Cognitive Dysfunction, Humans, Positron-Emission Tomography, tau Proteins ,
Molecular Imaging Approaches in Dementia Villemagne 2021 AMYPAD Dementia / diagnostic imaging* Disease Progression Early Diagnosis Humans Molecular Imaging, Neuroimaging, Positron-Emission Tomography, Prognosis, Radiopharmaceuticals, Tomography, Emission-Computed, Single-Photon ,
Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives Cotta Ramusino 2021 AMYPAD Outcome, Clinical utility, Amyloid-PET, Diagnostic biomarkers, Alzheimer’s disease, Systematic review
Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging Lopes 2021 AMYPAD PET imaging, Amyloid, Alzheimer’s disease, Prevention, Sample size, Clinical trial
Test-Retest Variability of Relative Tracer Delivery Rate as Measured by [11C]PiB Heeman 2021 AMYPAD [11C]PiB, Alzheimer’s disease, Cerebral blood flow, Relative tracer delivery, Test-retest variability
Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals Collij 2021 AMYPAD Alzheimer's disease, amyloid beta, longitudinal, positron emission tomography, regional
Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease Pfeil 2021 AMYPAD Alzheimer's disease, Mild cognitive impairment, Regional amyloid burden, Positron emission tomography, Disease progression, Amyloid-beta
Genetically identical twins show comparable tau PET load and spatial distribution Coomans 2022 AMYPAD Alzheimer’s disease, tau, PET, twins, genetics, alzheimer's disease, tau, proteins, monozygotic twins, genetics, pathology
Spatial-Temporal Patterns of Amyloid-β Accumulation: A Subtype and Stage Inference Model Analysis Colij 2022 AMYPAD amyloid; occipital; subtypes; amyloid-PET; ALFA+, EMIF-AD, ABIDE, OASIS, ADNI; APOE; Alzheimer's disease, risk factors
Should Doctors Offer Biomarker Testing to Those Afraid to Develop Alzheimer’s Dementia? Smedinga 2022 AMYPAD Bioethics, Alzheimer’s disease, Risk testing, Clinical ethics, Biomarkers
Quantification of amyloid PET for future clinical use: a state-of-the-art review Pemberton 2022 AMYPAD Brain, Amyloid, PET, Quantification, Alzheimer’s, Dementia, Centiloid, SUVr
Impact of cerebral blood flow and amyloid load on SUVR bias Heeman 2022 AMYPAD Alzheimer’s disease, Amyloid PET, Cerebral blood flow, Quantification, SUVR bias
Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study Altomare 2022 AMYPAD Alzheimer's; PET; amyloid; dementia; memory clinic population; mild cognitive impairment; subjective cognitive decline.
Regional associations of white matter hyperintensities and early cortical amyloid pathology Lorenzini 2022 AMYPAD White matter hyperintensities, amyloid PET, regional associations, multivariate analysis, pre-dementia population
Title Description Type Project  
Diagnostic and Prognostic study (DPMS)

The AMYPAD DPMS will select and follow-up a memory clinic population suspected of possible AD, focusing on those with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and dementia where AD is in the differential diagnosis (900 subjects in 3 strata: SCD plus, MCI, dementia possibly due to AD), to determine the usefulness of β-amyloid imaging with regards to diagnostic confidence, decision trees, change in diagnosis, and alterations between planned and actual patient management plans. There are 8 active sites, 617 reserach participants and 408 scans performed (Last update January 2020). For more information please visit:

cohort-clinical-amypad-1 AMYPAD
Prognostic and Natural History study (PNHS)

The AMYPAD PNHS will select and follow-up a natural history population ranging from cognitively normal, through subjective cognitive decline (SCD) towards mild cognitive impairment (MCI) due to early AD to better understand the natural history of the early disease phases and to evaluate the value of quantitative PET amyloid imaging measures for predicting progression within an Alzheimer's disease risk probability spectrum based on quantitative PET amyloid imaging measures, with or without other biomarkers through an intimate collaboration with EPAD and other non-EPAD cohorts. There are 9 active sites, 2 parent cohorts, 378 research participants and 297 scans performed (Last update January 2020). For more information, please visit:

cohort-clinical-amypad-2 AMYPAD
Neuroimaging datasets from the AMYPAD PNHS and DPMS studies

AMYPAD's PET and MRI imaging data set releases will be made available via collaborative workspaces. These data set releases will only include de-identified and cleaned data, from the Diagnostic and Patient Management Study (DPMS) and the Prognostic and Natural History Study (PNHS). Recruitment of the DPMS should be completed in 2020, with results expected in 2021. The data management activities have been started to ensure a clean dataset for the next step of data analysis. Recruitment of the PNHS is ongoing. The AMYPAD PNHS data will be made publicly available in the future. In line with the EPAD project, data locks will occur at least at V.1000, V.1500 and V.2000. Information on the PNHS data dictionary can be found here: For more information on the AMYPAD imaging datasets, please visit:

dataset-clinical-amypad-9 AMYPAD

"NiftyPET is an open source software solution for standalone and high-throughput PET image reconstruction and analysis. The key computational routines are written in CUDA C for fast and efficient processing on NVIDIA GPU devices. The routines are then embedded in Python C extensions to be readily available for high level programming in Python. The purpose of this software platform is to enable rapid processing of raw data as wells as image data for fully controlled quantitative PET image reconstruction and analysis. NiftyPET includes two stand-alone and independent Python packages: nipet and nimpa, which are dedicated to high-throughput image reconstruction and analysis. Strong emphasis is put on the data, which are acquired using positron emission tomography (PET) and magnetic resonance (MR), especially the hybrid and simultaneous PET/MR scanners."

tools-clinical-amypad-16 AMYPAD


Back to list